|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||148,426 g/mol|
|(what is this?)|
Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).
In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted.
The drug was developed by IDEC Pharmaceuticals Corporation.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Toralizumab, American Medical Association.
- Luebke, Robert W; Robert V House; Ian Kimber (2007). Immunotoxicology and immunopharmacology. Target Organ Toxicology Series (3 ed.). Boca Raton, Florida: CRC Press, Taylor & Francis Group. p. 131. ISBN 0-8493-3790-9.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|